Anemia Drugs May Not Be Safe At Low Levels: FDA
The target drugs, erythropoiesis-stimulating agents Aransep, Epogen and Procrit, were first slapped with the black-box warning—the FDA's strongest—in March.
All three drugs are taken by anemic patients with chronic kidney failure as well as cancer patients whose chemotherapy triggered anemia, although the latter...
To view the full article, register now.
Try Law360 FREE for seven days
Already a subscriber? Click here to login